Primary endpoint results of a phase II study of vascular endothelial growth factor trap-eye in wet age-related macular degeneration

To evaluate the biologic effects and safety of vascular endothelial growth factor (VEGF) Trap-Eye during a 12-week fixed-dosing period in patients with neovascular (wet) age-related macular degeneration (AMD). Multicenter, prospective, randomized, double-masked clinical trial with initial 12-week fi...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Ophthalmology (Rochester, Minn.) Ročník 118; číslo 6; s. 1089
Hlavní autoři:	Brown, David M, Heier, Jeffrey S, Ciulla, Thomas, Benz, Matthew, Abraham, Prema, Yancopoulos, George, Stahl, Neil, Ingerman, Avner, Vitti, Robert, Berliner, Alyson J, Yang, Ke, Nguyen, Quan Dong
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States 01.06.2011
Témata:	Aged Aged, 80 and over Choroidal Neovascularization - diagnosis Choroidal Neovascularization - etiology Choroidal Neovascularization - prevention & control Dose-Response Relationship, Drug Double-Blind Method Drug Administration Schedule Female Follow-Up Studies Fovea Centralis - drug effects Fovea Centralis - pathology Humans Intravitreal Injections Male Middle Aged Prospective Studies Treatment Outcome Vascular Endothelial Growth Factor A - administration & dosage Vascular Endothelial Growth Factor A - therapeutic use Visual Acuity Wet Macular Degeneration - complications Wet Macular Degeneration - diagnosis Wet Macular Degeneration - drug therapy
ISSN:	1549-4713, 1549-4713
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Abstract	To evaluate the biologic effects and safety of vascular endothelial growth factor (VEGF) Trap-Eye during a 12-week fixed-dosing period in patients with neovascular (wet) age-related macular degeneration (AMD). Multicenter, prospective, randomized, double-masked clinical trial with initial 12-week fixed dosing period. Data were analyzed to week 16. We included 159 patients with subfoveal choroidal neovascularization secondary to wet AMD. Patients were randomized 1:1:1:1:1 to VEGF Trap-Eye during the fixed-dosing phase (day 1 to week 12): 0.5 or 2 mg every 4 weeks (0.5 mg q4wk, 2 mg q4wk) on day 1 and at weeks 4, 8, and 12; or 0.5, 2, or 4 mg every 12 weeks (0.5 mg q12wk, 2 mg q12wk, or 4 mg q12wk) on day 1 and at week 12. The primary endpoint was change from baseline in central retinal/lesion thickness (CR/LT) at week 12; secondary outcomes included change in best-corrected visual acuity (BCVA), proportion of patients with a gain of ≥ 15 letters, proportion of patients with a loss of >15 letters, and safety. At week 12, treatment with VEGF Trap-Eye resulted in a significant mean decrease in CR/LT of 119 μm from baseline in all groups combined (P<0.0001). The reduction in CR/LT with the 2 mg q4wk and 0.5mg q4wk regimens was significantly greater than each of the quarterly dosing regimens. The BCVA increased significantly by a mean of 5.7 letters at 12 weeks in the combined group (P<0.0001), with the greatest mean gain of >8 letters in the monthly dosing groups. At 8 weeks, BCVA improvements were similar with 2 mg q4wk and 2 mg q12wk dosing. After the last required dose at week 12, CR/LT and visual acuity were maintained or further improved at week 16 in all treatment groups. Ocular adverse events were mild and consistent with safety profiles reported for other intraocular anti-VEGF treatments. Repeated monthly intravitreal dosing of VEGF Trap-Eye over 12 weeks demonstrated significant reductions in retinal thickness and improvements in visual acuity, and was well-tolerated in patients with neovascular AMD. Proprietary or commercial disclosure may be found after the references.
AbstractList	To evaluate the biologic effects and safety of vascular endothelial growth factor (VEGF) Trap-Eye during a 12-week fixed-dosing period in patients with neovascular (wet) age-related macular degeneration (AMD). Multicenter, prospective, randomized, double-masked clinical trial with initial 12-week fixed dosing period. Data were analyzed to week 16. We included 159 patients with subfoveal choroidal neovascularization secondary to wet AMD. Patients were randomized 1:1:1:1:1 to VEGF Trap-Eye during the fixed-dosing phase (day 1 to week 12): 0.5 or 2 mg every 4 weeks (0.5 mg q4wk, 2 mg q4wk) on day 1 and at weeks 4, 8, and 12; or 0.5, 2, or 4 mg every 12 weeks (0.5 mg q12wk, 2 mg q12wk, or 4 mg q12wk) on day 1 and at week 12. The primary endpoint was change from baseline in central retinal/lesion thickness (CR/LT) at week 12; secondary outcomes included change in best-corrected visual acuity (BCVA), proportion of patients with a gain of ≥ 15 letters, proportion of patients with a loss of >15 letters, and safety. At week 12, treatment with VEGF Trap-Eye resulted in a significant mean decrease in CR/LT of 119 μm from baseline in all groups combined (P<0.0001). The reduction in CR/LT with the 2 mg q4wk and 0.5mg q4wk regimens was significantly greater than each of the quarterly dosing regimens. The BCVA increased significantly by a mean of 5.7 letters at 12 weeks in the combined group (P<0.0001), with the greatest mean gain of >8 letters in the monthly dosing groups. At 8 weeks, BCVA improvements were similar with 2 mg q4wk and 2 mg q12wk dosing. After the last required dose at week 12, CR/LT and visual acuity were maintained or further improved at week 16 in all treatment groups. Ocular adverse events were mild and consistent with safety profiles reported for other intraocular anti-VEGF treatments. Repeated monthly intravitreal dosing of VEGF Trap-Eye over 12 weeks demonstrated significant reductions in retinal thickness and improvements in visual acuity, and was well-tolerated in patients with neovascular AMD. Proprietary or commercial disclosure may be found after the references. To evaluate the biologic effects and safety of vascular endothelial growth factor (VEGF) Trap-Eye during a 12-week fixed-dosing period in patients with neovascular (wet) age-related macular degeneration (AMD).OBJECTIVETo evaluate the biologic effects and safety of vascular endothelial growth factor (VEGF) Trap-Eye during a 12-week fixed-dosing period in patients with neovascular (wet) age-related macular degeneration (AMD).Multicenter, prospective, randomized, double-masked clinical trial with initial 12-week fixed dosing period. Data were analyzed to week 16.DESIGNMulticenter, prospective, randomized, double-masked clinical trial with initial 12-week fixed dosing period. Data were analyzed to week 16.We included 159 patients with subfoveal choroidal neovascularization secondary to wet AMD.PARTICIPANTSWe included 159 patients with subfoveal choroidal neovascularization secondary to wet AMD.Patients were randomized 1:1:1:1:1 to VEGF Trap-Eye during the fixed-dosing phase (day 1 to week 12): 0.5 or 2 mg every 4 weeks (0.5 mg q4wk, 2 mg q4wk) on day 1 and at weeks 4, 8, and 12; or 0.5, 2, or 4 mg every 12 weeks (0.5 mg q12wk, 2 mg q12wk, or 4 mg q12wk) on day 1 and at week 12.METHODSPatients were randomized 1:1:1:1:1 to VEGF Trap-Eye during the fixed-dosing phase (day 1 to week 12): 0.5 or 2 mg every 4 weeks (0.5 mg q4wk, 2 mg q4wk) on day 1 and at weeks 4, 8, and 12; or 0.5, 2, or 4 mg every 12 weeks (0.5 mg q12wk, 2 mg q12wk, or 4 mg q12wk) on day 1 and at week 12.The primary endpoint was change from baseline in central retinal/lesion thickness (CR/LT) at week 12; secondary outcomes included change in best-corrected visual acuity (BCVA), proportion of patients with a gain of ≥ 15 letters, proportion of patients with a loss of >15 letters, and safety.MAIN OUTCOME MEASURESThe primary endpoint was change from baseline in central retinal/lesion thickness (CR/LT) at week 12; secondary outcomes included change in best-corrected visual acuity (BCVA), proportion of patients with a gain of ≥ 15 letters, proportion of patients with a loss of >15 letters, and safety.At week 12, treatment with VEGF Trap-Eye resulted in a significant mean decrease in CR/LT of 119 μm from baseline in all groups combined (P<0.0001). The reduction in CR/LT with the 2 mg q4wk and 0.5mg q4wk regimens was significantly greater than each of the quarterly dosing regimens. The BCVA increased significantly by a mean of 5.7 letters at 12 weeks in the combined group (P<0.0001), with the greatest mean gain of >8 letters in the monthly dosing groups. At 8 weeks, BCVA improvements were similar with 2 mg q4wk and 2 mg q12wk dosing. After the last required dose at week 12, CR/LT and visual acuity were maintained or further improved at week 16 in all treatment groups. Ocular adverse events were mild and consistent with safety profiles reported for other intraocular anti-VEGF treatments.RESULTSAt week 12, treatment with VEGF Trap-Eye resulted in a significant mean decrease in CR/LT of 119 μm from baseline in all groups combined (P<0.0001). The reduction in CR/LT with the 2 mg q4wk and 0.5mg q4wk regimens was significantly greater than each of the quarterly dosing regimens. The BCVA increased significantly by a mean of 5.7 letters at 12 weeks in the combined group (P<0.0001), with the greatest mean gain of >8 letters in the monthly dosing groups. At 8 weeks, BCVA improvements were similar with 2 mg q4wk and 2 mg q12wk dosing. After the last required dose at week 12, CR/LT and visual acuity were maintained or further improved at week 16 in all treatment groups. Ocular adverse events were mild and consistent with safety profiles reported for other intraocular anti-VEGF treatments.Repeated monthly intravitreal dosing of VEGF Trap-Eye over 12 weeks demonstrated significant reductions in retinal thickness and improvements in visual acuity, and was well-tolerated in patients with neovascular AMD.CONCLUSIONSRepeated monthly intravitreal dosing of VEGF Trap-Eye over 12 weeks demonstrated significant reductions in retinal thickness and improvements in visual acuity, and was well-tolerated in patients with neovascular AMD.Proprietary or commercial disclosure may be found after the references.FINANCIAL DISCLOSURE(S)Proprietary or commercial disclosure may be found after the references.
Author	Stahl, Neil Vitti, Robert Yancopoulos, George Ciulla, Thomas Abraham, Prema Yang, Ke Brown, David M Heier, Jeffrey S Ingerman, Avner Berliner, Alyson J Benz, Matthew Nguyen, Quan Dong
Author_xml	– sequence: 1 givenname: David M surname: Brown fullname: Brown, David M email: dmbmd@houstonretina.com organization: Retina Consultants of Houston, The Methodist Hospital, Houston, Texas, USA. dmbmd@houstonretina.com – sequence: 2 givenname: Jeffrey S surname: Heier fullname: Heier, Jeffrey S – sequence: 3 givenname: Thomas surname: Ciulla fullname: Ciulla, Thomas – sequence: 4 givenname: Matthew surname: Benz fullname: Benz, Matthew – sequence: 5 givenname: Prema surname: Abraham fullname: Abraham, Prema – sequence: 6 givenname: George surname: Yancopoulos fullname: Yancopoulos, George – sequence: 7 givenname: Neil surname: Stahl fullname: Stahl, Neil – sequence: 8 givenname: Avner surname: Ingerman fullname: Ingerman, Avner – sequence: 9 givenname: Robert surname: Vitti fullname: Vitti, Robert – sequence: 10 givenname: Alyson J surname: Berliner fullname: Berliner, Alyson J – sequence: 11 givenname: Ke surname: Yang fullname: Yang, Ke – sequence: 12 givenname: Quan Dong surname: Nguyen fullname: Nguyen, Quan Dong
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/21640257$$D View this record in MEDLINE/PubMed
BookMark	eNpNkE1Lw0AYhBep2A_9ByJ785S4H8kmOUrxo1DQg57D2-ybJmWbjbsbS8_-cVtawdMMwzNzmCkZdbZDQm45iznj6mET274JDcSCcR4zETNZXJAJT5MiSjIuR__8mEy93zDGlJLJFRkLrhIm0mxCft5duwW3p9jp3rZdoA79YIKntqZA-wY80sWC-jDo_TH7Bl8NBtyxYEODpgVD187uQkNrqIJ1NDjoI9wjbTu6w0BhjZFDAwE13cKprXGNHToIre2uyWUNxuPNWWfk8_npY_4aLd9eFvPHZVSlKg2RyrO6KDhykdVMIbCsElIdvE5XoJKca54oBTKHWotKMF0nmK8KqfNcQqGlmJH7027v7NeAPpTb1ldoDHRoB1_mGUtTxrP8QN6dyWG1RV32p5PKv9_EL0PZdUY
CitedBy_id	crossref_primary_10_1007_s00417_019_04347_6 crossref_primary_10_1007_s40123_024_00994_z crossref_primary_10_1155_2013_830837 crossref_primary_10_1097_IAE_0b013e31828e8551 crossref_primary_10_1007_s12325_022_02248_5 crossref_primary_10_1016_j_toxlet_2021_01_006 crossref_primary_10_1016_j_yoph_2011_11_001 crossref_primary_10_1517_14712598_2016_1167182 crossref_primary_10_1155_2018_8310350 crossref_primary_10_1097_IAE_0b013e318271f265 crossref_primary_10_1016_j_ophtha_2012_01_042 crossref_primary_10_1155_2011_752543 crossref_primary_10_1586_17469899_2013_814904 crossref_primary_10_1177_2040622312446007 crossref_primary_10_1038_eye_2017_67 crossref_primary_10_1136_bjophthalmol_2016_309376 crossref_primary_10_1186_s12886_021_01816_7 crossref_primary_10_1310_hpj4705_375 crossref_primary_10_1016_j_preteyeres_2015_06_004 crossref_primary_10_1097_IAE_0000000000002582 crossref_primary_10_1080_17469899_2018_1468250 crossref_primary_10_1586_eop_11_55 crossref_primary_10_2217_imt_12_158 crossref_primary_10_1172_JCI70230 crossref_primary_10_25122_jml_2022_0356 crossref_primary_10_1016_j_survophthal_2012_01_007 crossref_primary_10_1016_j_exer_2018_03_010 crossref_primary_10_1007_s00417_025_06930_6 crossref_primary_10_12968_opti_2016_4_123 crossref_primary_10_1007_s10456_011_9249_6 crossref_primary_10_1007_s00417_019_04361_8 crossref_primary_10_4137_CMT_S8921 crossref_primary_10_1111_cxo_12120 crossref_primary_10_1016_j_csda_2016_08_007 crossref_primary_10_3389_fddev_2024_1337686 crossref_primary_10_1185_03007995_2015_1084909 crossref_primary_10_1007_s13554_012_0003_4 crossref_primary_10_1080_14656566_2024_2354921 crossref_primary_10_1177_1120672119848961 crossref_primary_10_1007_s40266_014_0176_2 crossref_primary_10_1097_ICU_0000000000000257 crossref_primary_10_1016_j_ophtha_2012_09_006 crossref_primary_10_1016_j_ajo_2019_02_027 crossref_primary_10_3928_23258160_20160419_09 crossref_primary_10_1007_s40123_013_0015_2 crossref_primary_10_1155_2017_6145651 crossref_primary_10_1517_14712598_2012_707176 crossref_primary_10_1016_j_cct_2014_02_003 crossref_primary_10_1007_s40266_012_0015_2 crossref_primary_10_1586_ecp_12_81 crossref_primary_10_3390_biom12111629 crossref_primary_10_1097_IAE_0000000000001590 crossref_primary_10_1016_j_survophthal_2012_11_006 crossref_primary_10_1016_j_exer_2013_05_006 crossref_primary_10_4103_ijo_IJO_1026_15 crossref_primary_10_1016_j_ajo_2012_10_019 crossref_primary_10_1016_j_ijpharm_2024_124258 crossref_primary_10_1016_j_omtm_2019_05_007 crossref_primary_10_1159_000445724 crossref_primary_10_1007_s40123_023_00854_2 crossref_primary_10_1016_j_ajo_2012_04_020 crossref_primary_10_1517_14656566_2012_658368 crossref_primary_10_3390_ijms23169424
ContentType	Journal Article
Copyright	Copyright © 2011 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.
Copyright_xml	– notice: Copyright © 2011 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.
CorporateAuthor	CLEAR-IT 2 Investigators
CorporateAuthor_xml	– name: CLEAR-IT 2 Investigators
DBID	CGR CUY CVF ECM EIF NPM 7X8
DOI	10.1016/j.ophtha.2011.02.039
DatabaseName	Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic
DatabaseTitle	MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE MEDLINE - Academic
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	no_fulltext_linktorsrc
Discipline	Medicine
EISSN	1549-4713
ExternalDocumentID	21640257
Genre	Multicenter Study Clinical Trial, Phase II Comparative Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article
GroupedDBID	--- --K .1- .55 .FO .GJ 0R~ 123 1B1 1P~ 1~5 29N 4.4 457 4G. 53G 5RE 5VS 7-5 71M AAEDT AAEDW AALRI AAQFI AAQQT AAQXK AAXUO ABCQX ABFRF ABJNI ABLJU ABMAC ABOCM ABWVN ACGFO ACGFS ACIUM ACNCT ACRPL ADMUD ADNMO AEFWE AENEX AEVXI AFFNX AFJKZ AFRHN AFTJW AITUG AJUYK AKRWK ALMA_UNASSIGNED_HOLDINGS AMRAJ BELOY C5W CGR CS3 CUY CVF DU5 EBS ECM EFJIC EIF EJD F5P FDB FEDTE FGOYB GBLVA HVGLF HZ~ IHE J1W K-O KOM L7B M27 M41 MO0 N4W N9A NPM NQ- O9- OF- OPF OQ~ P2P R2- RIG ROL RPZ SDG SEL SES SSZ UHS UNMZH UV1 WH7 X7M XH2 XPP Z5R ZGI ZXP 7X8 EFKBS
ID	FETCH-LOGICAL-c565t-687f991e127f06ea07c2367f0d5ba6481d1466a38afd2c20df4e8b93d883a9d32
IEDL.DBID	7X8
ISICitedReferencesCount	83
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000291152700014&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1549-4713
IngestDate	Thu Oct 02 11:42:08 EDT 2025 Thu Apr 03 06:57:00 EDT 2025
IsPeerReviewed	true
IsScholarly	true
Issue	6
Language	English
License	Copyright © 2011 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c565t-687f991e127f06ea07c2367f0d5ba6481d1466a38afd2c20df4e8b93d883a9d32
Notes	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Undefined-3
PMID	21640257
PQID	870550178
PQPubID	23479
ParticipantIDs	proquest_miscellaneous_870550178 pubmed_primary_21640257
PublicationCentury	2000
PublicationDate	2011-06-01
PublicationDateYYYYMMDD	2011-06-01
PublicationDate_xml	– month: 06 year: 2011 text: 2011-06-01 day: 01
PublicationDecade	2010
PublicationPlace	United States
PublicationPlace_xml	– name: United States
PublicationTitle	Ophthalmology (Rochester, Minn.)
PublicationTitleAlternate	Ophthalmology
PublicationYear	2011
SSID	ssj0006634
Score	2.3274848
Snippet	To evaluate the biologic effects and safety of vascular endothelial growth factor (VEGF) Trap-Eye during a 12-week fixed-dosing period in patients with...
SourceID	proquest pubmed
SourceType	Aggregation Database Index Database
StartPage	1089
SubjectTerms	Aged Aged, 80 and over Choroidal Neovascularization - diagnosis Choroidal Neovascularization - etiology Choroidal Neovascularization - prevention & control Dose-Response Relationship, Drug Double-Blind Method Drug Administration Schedule Female Follow-Up Studies Fovea Centralis - drug effects Fovea Centralis - pathology Humans Intravitreal Injections Male Middle Aged Prospective Studies Treatment Outcome Vascular Endothelial Growth Factor A - administration & dosage Vascular Endothelial Growth Factor A - therapeutic use Visual Acuity Wet Macular Degeneration - complications Wet Macular Degeneration - diagnosis Wet Macular Degeneration - drug therapy
Title	Primary endpoint results of a phase II study of vascular endothelial growth factor trap-eye in wet age-related macular degeneration
URI	https://www.ncbi.nlm.nih.gov/pubmed/21640257 https://www.proquest.com/docview/870550178
Volume	118
WOSCitedRecordID	wos000291152700014&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings	1
isFullTextHit
isPrint
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8QwEA6-EC--3w_m4DWaTWqbnkREUdBlDwp7W5Jm4i5oW92qePaPO2m7etODlx4KgTKZznzz-oaxQyu8yGJMuXRG8shK5DrKNLfkzTveIUbNTd8k3a7u99Ne25szbtsqJzaxNtSuyEKO_FgH2pewS_60fOZhaVQorrYbNKbZrCIkE5Q66f-QhZMzrYvKFAJxssFqMjlXt3cV5bAampbDUx4J9QvGrH3N5dI_v3KZLbYgE84arVhhU5ivsvnbtoy-xj57DccEYO7KYpRXQEH362M1hsKDgXJIrg2ur6Hmng3vJv2q4UAY2XokrYUHiuCrITQbe6B6MSXHD4RRDu9YAdkpXg_KoIMn05x2-FCzXAdlWGf3lxd351e83cbAMwJ9FY914glMYkcmXsRoRJIF9jcv3Ik1cUS4l4xubJQ23slMCucj1DZVTmtlUqfkBpvJixy3GJyopNNx3nkrbKQyaVNh08ALlLrYYCK2GUykOyBtDyUMk2PxOh58y3ebbTY3NCgbiQ0kBX4E4JKdvw_vsoUmNRySKXts1tOfjvtsLnurRuOXg1qL6Nnt3X4BzPbUGw
linkProvider	ProQuest
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Primary+endpoint+results+of+a+phase+II+study+of+vascular+endothelial+growth+factor+trap-eye+in+wet+age-related+macular+degeneration&rft.jtitle=Ophthalmology+%28Rochester%2C+Minn.%29&rft.au=Brown%2C+David+M&rft.au=Heier%2C+Jeffrey+S&rft.au=Ciulla%2C+Thomas&rft.au=Benz%2C+Matthew&rft.date=2011-06-01&rft.eissn=1549-4713&rft.volume=118&rft.issue=6&rft.spage=1089&rft_id=info:doi/10.1016%2Fj.ophtha.2011.02.039&rft_id=info%3Apmid%2F21640257&rft_id=info%3Apmid%2F21640257&rft.externalDocID=21640257
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1549-4713&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1549-4713&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1549-4713&client=summon